2023
Machine learning-based prediction of clinical outcomes after first-ever ischemic stroke
Fast L, Temuulen U, Villringer K, Kufner A, Ali H, Siebert E, Huo S, Piper S, Sperber P, Liman T, Endres M, Ritter K. Machine learning-based prediction of clinical outcomes after first-ever ischemic stroke. Frontiers In Neurology 2023, 14: 1114360. PMID: 36895902, PMCID: PMC9990416, DOI: 10.3389/fneur.2023.1114360.Peer-Reviewed Original ResearchMini-Mental State ExaminationClinical outcomesBarthel IndexIschemic strokePrognostic factorsPatient dischargeCognitive functionFunctional recovery outcomesFurther patient careHealth Stroke ScaleEpidemiologic Studies Depression ScaleIschemic stroke patientsStroke ScaleAcute strokeProspective cohortRankin ScaleFunctional recoveryPrognostic featuresStroke patientsModified Telephone InterviewTreatment strategiesDepression ScaleIndividual patientsState ExaminationHealthcare providers
2019
Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B)
Sperber P, Siegerink B, Huo S, Rohmann J, Piper S, Prüss H, Heuschmann P, Endres M, Liman T. Serum Anti-NMDA (N-Methyl-D-Aspartate)-Receptor Antibodies and Long-Term Clinical Outcome After Stroke (PROSCIS-B). Stroke 2019, 50: 3213-3219. PMID: 31526121, DOI: 10.1161/strokeaha.119.026100.Peer-Reviewed Original ResearchConceptsSecondary vascular eventsFunctional outcomeVascular eventsHigh titersNMDAR1-ABSeronegative patientsSeropositive patientsFirst strokeLong-term clinical outcomesLong-term functional outcomeCombined end pointRecurrent vascular eventsOutcomes of patientsPoor functional outcomeSub-group analysisOutcomes of interestAnti-NMDAAutoimmune encephalitisCardiovascular riskProspective cohortRankin ScaleHazard ratioClinical outcomesNeuroprotective effectsReceptor antibodies